WEKO3
アイテム
{"_buckets": {"deposit": "9d147e54-7763-4fe3-ac65-c6f5694de3d9"}, "_deposit": {"created_by": 1, "id": "70586", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "70586"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00070586", "sets": ["28"]}, "author_link": ["693258", "693260", "693261", "693259", "693256", "693257"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2011-10-19", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Aim: The aim of the clinical study is to investigate whether PET imaging with a hypoxia tracer [18F]fluoroazomycin arabinoside (FAZA) can discriminate between radioresistant and radiosensitive cancers in histologically-proven primary lung cancer patients planned for radiotherapy. Here shown are the initial results on the [18F]FAZA uptake to the primary lesions.\nMaterials \u0026 Methods: Eighteen primary lung cancer patients were enrolled (63 +- 9 y/o, male: female = 11: 7, adenocarcinomas: squamous cell carcinomas: large cell carcinomas = 9: 5: 4, clinical stage IIIA: IIIB: IV = 7: 7: 4). [18F]FAZA-PET images were obtained 2 hours after the tracer injection (370 MBq). The standardized uptake values (SUV), the tumor-to-contralateral normal lung (T/N) ratio, the tumor-to-blood measured in the left ventricle (T/Bl) ratio, and the tumor-to-buck muscles (T/M) ratio were calculated as the semiquantitative parameters for [18F]FAZA uptakes to the primary lesions under the guidance of concomitant CT images. The SUV of [18F]Fluorodeoxylucose (FDG) was also compared with these parameters.\nResults: There was no statistical difference in the maximum tumor diameter or in the SUV of [18F]FDG between genders, among histological types, or among clinical stages. The T/N ratio of [18F]FAZA was significantly higher in patients with large cell carcinomas than those with adenocarcinomas (5.0 +- 1.9 vs 2.5 +- 0.9, p \u003c 0.0001). The T/Bl ratio of [18F]FAZA was significantly correlated with the maximum tumor diameter (R2 = 0.670, p \u003c 0.0001) and with the SUV of [18F]FDG (R2 = 0.507, p \u003c 0.0001), as well as with the SUV of [18F]FAZA (R2 = 0.748, p \u003c 0.0001). The T/M ratio, however, seemed inappropriate as the parameter in lung cancer, since there was a gender difference in the SUV of [18F]FAZA to the buck muscles themselves (male 1.45 +- 0.12 vs female 1.26 +- 0.19, p = 0.02).\nConclusion: Histological difference was found in a parameter of [18F]FAZA uptake to the primary lesions in the lung cancer patients. In addition, reasonable relationships with the tumor size and with the tumor [18F]FDG uptake was found in another parameter of the [18F]FAZA uptake. The best parameter of the [18F]FAZA uptake for predicting the resistance to radiotherapy will be determined through following up the therapeutic outcome of these patients. (364 words)", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "EANM\u002711 - Annual Congress of the European Association of Nuclear Medicine", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Inubushi, Masayuki"}], "nameIdentifiers": [{"nameIdentifier": "693256", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Koizumi, Mitsuru"}], "nameIdentifiers": [{"nameIdentifier": "693257", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saga, Tsuneo"}], "nameIdentifiers": [{"nameIdentifier": "693258", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "犬伏 正幸", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "693259", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "小泉 満", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "693260", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "佐賀 恒夫", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "693261", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Initial Report on [18F]FAZA-PET/CT Clinical Study in Lung Cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Initial Report on [18F]FAZA-PET/CT Clinical Study in Lung Cancer"}]}, "item_type_id": "10005", "owner": "1", "path": ["28"], "permalink_uri": "https://repo.qst.go.jp/records/70586", "pubdate": {"attribute_name": "公開日", "attribute_value": "2011-10-26"}, "publish_date": "2011-10-26", "publish_status": "0", "recid": "70586", "relation": {}, "relation_version_is_last": true, "title": ["Initial Report on [18F]FAZA-PET/CT Clinical Study in Lung Cancer"], "weko_shared_id": -1}
Initial Report on [18F]FAZA-PET/CT Clinical Study in Lung Cancer
https://repo.qst.go.jp/records/70586
https://repo.qst.go.jp/records/70586096d3fab-e7b6-42e4-9d72-61fad0aea7d7
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2011-10-26 | |||||
タイトル | ||||||
タイトル | Initial Report on [18F]FAZA-PET/CT Clinical Study in Lung Cancer | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Inubushi, Masayuki
× Inubushi, Masayuki× Koizumi, Mitsuru× Saga, Tsuneo× 犬伏 正幸× 小泉 満× 佐賀 恒夫 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Aim: The aim of the clinical study is to investigate whether PET imaging with a hypoxia tracer [18F]fluoroazomycin arabinoside (FAZA) can discriminate between radioresistant and radiosensitive cancers in histologically-proven primary lung cancer patients planned for radiotherapy. Here shown are the initial results on the [18F]FAZA uptake to the primary lesions. Materials & Methods: Eighteen primary lung cancer patients were enrolled (63 +- 9 y/o, male: female = 11: 7, adenocarcinomas: squamous cell carcinomas: large cell carcinomas = 9: 5: 4, clinical stage IIIA: IIIB: IV = 7: 7: 4). [18F]FAZA-PET images were obtained 2 hours after the tracer injection (370 MBq). The standardized uptake values (SUV), the tumor-to-contralateral normal lung (T/N) ratio, the tumor-to-blood measured in the left ventricle (T/Bl) ratio, and the tumor-to-buck muscles (T/M) ratio were calculated as the semiquantitative parameters for [18F]FAZA uptakes to the primary lesions under the guidance of concomitant CT images. The SUV of [18F]Fluorodeoxylucose (FDG) was also compared with these parameters. Results: There was no statistical difference in the maximum tumor diameter or in the SUV of [18F]FDG between genders, among histological types, or among clinical stages. The T/N ratio of [18F]FAZA was significantly higher in patients with large cell carcinomas than those with adenocarcinomas (5.0 +- 1.9 vs 2.5 +- 0.9, p < 0.0001). The T/Bl ratio of [18F]FAZA was significantly correlated with the maximum tumor diameter (R2 = 0.670, p < 0.0001) and with the SUV of [18F]FDG (R2 = 0.507, p < 0.0001), as well as with the SUV of [18F]FAZA (R2 = 0.748, p < 0.0001). The T/M ratio, however, seemed inappropriate as the parameter in lung cancer, since there was a gender difference in the SUV of [18F]FAZA to the buck muscles themselves (male 1.45 +- 0.12 vs female 1.26 +- 0.19, p = 0.02). Conclusion: Histological difference was found in a parameter of [18F]FAZA uptake to the primary lesions in the lung cancer patients. In addition, reasonable relationships with the tumor size and with the tumor [18F]FDG uptake was found in another parameter of the [18F]FAZA uptake. The best parameter of the [18F]FAZA uptake for predicting the resistance to radiotherapy will be determined through following up the therapeutic outcome of these patients. (364 words) |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | EANM'11 - Annual Congress of the European Association of Nuclear Medicine | |||||
発表年月日 | ||||||
日付 | 2011-10-19 | |||||
日付タイプ | Issued |